

1 **Impact of Retinopathy and Systemic Vascular Comorbidities on All-Cause Mortality**

2

3 **Running title:** Effects of retinopathy and comorbidities on mortality

4

5 **Authors:**

6 Zhuoting Zhu, MD, PhD^{1,2}

7 Xianwen Shang, PhD^{1,2}

8 Wei Wang, MD, PhD³

9 Jason Ha, MBBS²

10 Yifan Chen, BM BCh⁴

11 Jingyi He, MBBS⁵

12 Wenyi Hu, MBBS¹

13 Xiaohong Yang, MD, PhD¹

14 Mingguang He, MD, PhD^{1,2,3}

15

16 **Affiliations:**

17 1. Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial

18 People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 2. Centre for Eye Research Australia, Ophthalmology, Department of Surgery, University
20 of Melbourne, Melbourne, Australia.

21 3. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
22 University, Guangzhou, China.

23 4. Medical Sciences Division, University of Oxford, Oxford, England.

24 5. Sun Yat-sen University, Guangzhou, China.

25

26 Word count: Abstract, 193; Whole paper, 3036;

27 Tables: 3; Figures: 1; Supplement Tables: 7

28

29 **Corresponding author**

30 Mingguang He, MD PhD

31 ORCID ID: <https://orcid.org/0000-0002-6912-2810>

32 Email: mingguang.he@unimelb.edu.au

33 Xiaohong Yang, MD PhD

34 ORCID ID: <https://orcid.org/0000-0001-9466-7591>

35 Email: syyangxh@scut.edu.cn

36

37 **Abstract**

38 **Aims/hypothesis:**

39 To investigate the joint effects of retinopathy and systemic vascular comorbidities on
40 mortality.

41 **Methods:**

42 This study included 5703 participants (≥ 40 years old) from the 2005-2008 National Health
43 and Nutrition Examination Survey. The Early Treatment Diabetic Retinopathy Study grading
44 scale was used to evaluate the retinopathy status. Systemic vascular comorbidities included
45 diabetes mellitus (DM), high blood pressure (HBP), chronic kidney disease (CKD) and
46 cardiovascular disease (CVD). Time to death was calculated as the time from baseline to
47 either the date of death or censoring (December 31st, 2015), whichever came first. Risks of
48 mortality were estimated using Cox proportional hazards models.

49 **Results:**

50 After adjusting for confounders, the presence of retinopathy predicted higher all-cause
51 mortality (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.09-1.81). The all-cause
52 mortality among participants with both retinopathy and systemic vascular comorbidities
53 including DM (HR, 1.63; 95% CI, 1.06-2.50), HBP (HR, 1.46; 95% CI, 1.03-2.08), CKD
54 (HR, 1.71; 95% CI, 1.24-2.35) and CVD (HR, 1.88; 95% CI, 1.19-2.96) was significantly
55 higher than that among those without either condition.

56 **Conclusions/interpretation:**

57 In this prospective study, individuals with retinopathy had increased all-cause mortality. The
58 joint effects of retinopathy and major systemic vascular comorbidities increased the all-cause
59 mortality further, suggesting that more extensive vascular risk factor assessment and
60 management are needed to detect the burden of vascular pathologies and improve long-term
61 survival in individuals with retinopathy.

62

63 **Keywords** retinopathy; systemic vascular comorbidities; mortality.

64

65 **Research in context**

66 **What is already known about this subject?**

67 Retinopathy has been recognized as an independent risk factor for mortality.

68 **What is the key question?**

69 What are the joint effects of retinopathy and systemic vascular comorbidities (including
70 diabetes mellitus, hypertension and chronic kidney disease and cardiovascular disease) on
71 mortality?

72

73 **What are the new findings?**

74 Consistent evidence on the increased risk of mortality among individuals with retinopathy
75 was noted in a large sample of middle-aged and older adults.

76 The co-occurrence of retinopathy and systemic vascular conditions (diabetes mellitus,
77 hypertension and chronic kidney disease and cardiovascular disease) further increased all-
78 cause mortality independent of other covariates.

79

80 **How might this impact on clinical practice in the foreseeable future?**

81 Individuals with retinopathy may benefit from a comprehensive vascular assessment.

82 Intensive vascular risk reduction is needed in the management of patients with retinopathy
83 and and micro- or macrovascular disorders.

84 Highlighted the importance of retinopathy screening using retinal imaging for identifying
85 individuals at high risk of mortality, particularly among individuals with systemic vascular
86 comorbidities.

87 **Introduction**

88 Retinopathy commonly refers to a spectrum of signs on the fundus (e.g. microaneurysms,
89 soft/hard exudates, and/or retinal hemorrhage) that are common in the elderly, even in those
90 without diabetes.¹ A recent pooled analysis of 22,896 individuals with diabetes reported that
91 nearly 35% had retinopathy.² Furthermore, previous evidence suggested that up to 15% of
92 non-diabetic patients exhibited clinical signs of retinopathy.³⁻⁷

93 Previous literature has consistently described significant associations between
94 retinopathy and systemic vascular comorbidities, including diabetes mellitus (DM),⁵ high
95 blood pressure (HBP),⁸ chronic kidney disease (CKD)^{6, 9-11} and cardiovascular disease
96 (CVD).¹²⁻¹⁵ The presence of retinopathy has been reported to be an independent risk factor
97 for mortality.¹⁶⁻²⁷ A recent meta-analysis of 20 observational studies reported that individuals
98 with retinopathy had a two- to four-fold increase in their all-cause mortality independent of
99 other potential risk factors.²⁸

100 To date, only a few studies have investigated the joint effects of retinopathy and systemic
101 vascular comorbidities (such as DM,¹⁶ CKD,^{16, 29-31} and clinical cerebrovascular disease¹⁶) on
102 mortality. These previous studies were subject to selection bias, underestimation of
103 retinopathy, short duration of follow-up and a lack of investigation of the effects of
104 concomitant macrovascular disorders. Given that the retina is readily viewable via non-
105 invasive retinal imaging and that there is a well-established association between retinopathy
106 and systemic vascular comorbidities, clarifying the precise effects of the co-occurrence of
107 retinopathy and systemic vascular comorbidities on the risk of mortality is of great

108 significance.

109 The National Health and Nutrition Examination Survey (NHANES) is a large nationally
110 representative multiethnic sample of U.S. adults, with a standardized grading protocol for
111 retinopathy using photographs of two eyes, availability of death records from 2005 through
112 2015, information on macrovascular disorders and inclusion of a comprehensive range of
113 covariates. Therefore, the analysis based on the NHANES address previous limitations and
114 provide more robust estimates of impacts of retinopathy and systemic vascular comorbidities
115 on mortality.

116

117 **Methods**

118 **Sample and Population**

119 The NHANES dataset from 2005 to 2008 was used for the current analysis. NHANES
120 is a nationally representative survey of the non-institutionalized U.S. civilian population that
121 includes in-person interviews and extensive clinical examinations. As described in detail
122 elsewhere, the NHANES uses a multistage design to select participants from strata and
123 proportions of minority populations.³² Since 1999, the NHANES has released a dataset every
124 two years. Because of the availability of retinal imaging, two NHANES cycles (2005-2006
125 and 2007-2008) were merged. In total, 5,703 out of 6,797 individuals aged 40 years and older
126 were included for the current analysis. 1,093 participants were excluded due to missing
127 information on the grading of retinopathy for both eyes. One participant was excluded

128 because of the lack of mortality data.

129 The research adhered to the tenets of the Declaration of Helsinki. Written informed
130 consent was given by every participant, and the NHANES was conducted in accordance with
131 ethical standards. Because data used in this analysis were publicly available and de-identified,
132 the present study received exemption from review by the institutional review board.

133 **Evaluation of Retinopathy**

134 The Canon CR6-45NM Ophthalmic Digital Imaging System and Canon EOS 10D
135 digital camera (Canon USA Inc., One Canon Park, Melville, New York) were used to capture
136 non-mydriatic retinal photographs. Two digital images per eye (one for the macula and one
137 for the optic nerve) were taken in an almost completely dark room. Based on a modification
138 of the Airlie House classification system,^{33,34} graders in the University of Wisconsin Ocular
139 Epidemiologic Reading Center, Madison assessed the fundus photographs. Details of image
140 capture and grading of fundus photographs have been described in an earlier study.³⁵ The
141 Early Treatment Diabetic Retinopathy Study (ETDRS) grading scale was used to evaluate
142 the retinopathy severity.³³ Participants were classified as having no retinopathy (level 10-13),
143 minimal-to-mild non-proliferative retinopathy (minimal-to-mild NPR, level 14-31),
144 moderate-to-severe retinopathy non-proliferative retinopathy (moderate-to-severe NPR,
145 level 41-51) and proliferative retinopathy (PR, level ≥ 60) based on the eye with the worse
146 retinopathy level.

147 **Assessment of Systemic Vascular Comorbidities**

148 Systemic vascular comorbidities, including DM, HBP, CKD and self-reported history of
149 CVD, were assessed. Identification of DM was based on self-reported medical history, use
150 of insulin or antihyperglycaemic medications, or a glycosylated hemoglobin level exceeding
151 6.5%.³⁶ Identification of HBP was based on a self-reported physician diagnosis, use of
152 antihypertensive medications, or the average of three measurements of systolic ≥ 140 mmHg)
153 and/or the average of three measurements of diastolic blood pressure ≥ 90 mmHg). An
154 estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m² was used to as
155 the definition for CKD.³⁷ A self-reported physician diagnosis of coronary heart disease,
156 myocardial infarction, congestive heart failure, angina or stroke was used to identify the self-
157 reported history of CVD.

158 **Mortality Data**

159 Mortality status was determined by NHANES linked National Death Index (NDI)
160 public-access files through December 31, 2015. Based on a probabilistic matching algorithm,
161 mortality was ascertained from the NDI.³⁸ This linkage was performed by matching
162 participants' personal identification information, such as name, sex, date of birth, social
163 security number, between the NHANES and the NDI datasets. Participants not found to be
164 deceased were considered to be alive. The time between the date of the interview and the
165 date of death or end-of-study censoring (the 31st of December, 2015), whichever came first,
166 was calculated as the duration of follow-up.

167 **Covariates**

168 Ethnicity was classified into four groups: non-Hispanic white, non-Hispanic black,

169 Mexican American, and other. Two categories of marital status included unmarried or other,
170 and married or lived with a partner. Education level was classified into two groups: did not
171 complete a high school degree, and completed at least a high school degree. The poverty-
172 income ratio (PIR) was categorized into two groups: < 1.00 and ≥ 1.00 (poverty threshold)
173 respectively. Smoking status was classified into two groups: never, and former or current
174 smokers. Drinking status was classified into two groups: abstainer or former drinker, and
175 current drinker. Duration of diabetes was obtained from the questionnaire. Identification of
176 hypercholesterolaemia was based on the total cholesterol level (≥ 240 mg/dL) or the use of
177 antihyperlipidemic agents. Body mass index (BMI) was a value derived from the weight in
178 kilograms divided by the height in meters squared. A high C-reactive protein (CRP) was
179 defined as CRP level ≥ 1 mg/dL. Walking disability was based on self-reported responses to
180 the questionnaire or the requirement of special equipment to aid walking. Health status was
181 dichotomously classified into poor or fair, and good or excellent.

182 **Statistical Analysis**

183 The complex, stratified design of NHANES was taken into account for all analyses. The
184 means and standard errors (SEs), or numbers and weighted proportions were used to present
185 the baseline characteristics of the study population where appropriate. The design-adjusted
186 t-test or the Rao-Scott Pearson χ^2 were used to compare distributions for continuous or
187 categorical variables. We used Kaplan-Meier estimates to generate plots of survival curves
188 among participants with retinopathy and concomitant systemic vascular disorders, and log-
189 rank tests to compare survival distributions among these groups. We used Cox proportional

190 hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs)
191 for survival. Furthermore, Cox proportional hazard regression models were used to model
192 the relationship between all-cause mortality and exposures of retinopathy and systemic
193 vascular diseases according to a reference group of participants without retinopathy and
194 systemic vascular comorbidity. We also examined additional effects from vascular
195 comorbidities on all-cause mortality according to a reference group of those with either
196 retinopathy or systemic vascular comorbidity. In order to address the potential non-response
197 bias, we have built models for the probability of inclusion and using inverse probability
198 weighting in sensitivity analysis. We tested the proportional hazard assumption for each
199 variable in the Cox regression models by creating the time-dependent covariate (interaction
200 between the variable and survival time), with a p-value < 0.05 for the time-dependent
201 covariate indicating a violation of the assumption. We found that all variables included in
202 the Cox regression models were valid. Collinearity among variables was tested using the
203 variance inflation factor (VIF) procedure, and the average value was 1.28 in the present
204 analysis. We used Stata (ver. 14.0; StataCorp., College Station, TX) to perform all analyses.
205 A p-value of less than 0.05 was considered statistically significant.

206

207 **Results**

208 In total, there were 6,797 individuals aged 40 years and older from the NHANES 2005-
209 2008. Of these participants, 5,703 were included in the current analysis due to missing data
210 on fundus photography (n=969), ungradability of photographs for both eyes (n=124) and

211 missing data on vital status (n=1). Reasons for not undergoing fundus photography (n = 969)
212 included insufficient time (n = 539), physical limitation (n = 160), eye-specific limitation (n
213 = 24), participant's refusal (n = 110), communication problems (n = 26), and others (n=110).
214 Excluded participants were more likely to be older, black, poorly educated, unmarried or
215 other, have a lower level of household income, be unhealthier in terms of health-related
216 behaviors and systemic comorbidities, and have a greater risk of mortality when compared
217 to those with complete data. The characteristics of the excluded and the included participants
218 are shown in Supplement Table 1.

219 A total of 710 participants were identified as having retinopathy (weighted prevalence:
220 9.75%). Among them, 573 (86.2%) out of 710 participants had minimal-to-mild NPR, 106
221 (11.2%) had moderate-to-severe NPR and 31 (2.65%) had PR. The mean age of these
222 participants was 56.5 years (SE, 0.38), and 52.6% were women. The baseline characteristics
223 of participants by retinopathy status are presented in Table 1. Participants identified as having
224 retinopathy were more likely to be older, male, black, poorly educated, and lifetime
225 abstainers/former drinkers and to have higher BMI, walking disability, poor/fair self-rated
226 health status, and concomitant micro- and macrovascular pathologies (DM, HBP, CKD and
227 CVD) compared to those without retinopathy. No significant difference in other
228 characteristics was observed between these two groups. The baseline characteristics of
229 participants stratified by retinopathy severity are shown in Supplement Table 2.

230 The median duration of follow-up was 8.33 years (interquartile range [IQR]: 7.50-9.67
231 years). There were 949 (11.8%) deaths from all causes. Participants with retinopathy had

232 higher all-cause mortality than those without (23.0% versus 10.5%, t-test $P < 0.001$). The
233 baseline characteristics, including demographic factors, health-related behaviors and general
234 health characteristics for participants by survival status, are presented in Table 2. Several
235 covariates, including age, sex, ethnicity, educational attainment, types of marital status,
236 household income level, smoking status, alcohol consumption, the level of CRP, self-rated
237 health status, walking disability, and micro- and macrovascular disorders (DM, CKD and
238 history of CVD), were strongly associated with higher all-cause mortality in age- and sex-
239 adjusted models. Multivariate Cox regression models suggested that the presence of any
240 degree of retinopathy at baseline was associated with higher all-cause mortality (HR, 1.40;
241 95% CI, 1.09-1.81; $P=0.011$). There was a significant trend toward higher all-cause mortality
242 risk across the retinopathy severity groups (P for trend = 0.010), where the greatest risk for
243 all-cause mortality was among those with moderate-to-severe NPR or PR (HR=1.77, 95%
244 CI: 1.04-3.03, $P = 0.037$).

245 Interactions between retinopathy and each systemic vascular disorder were assessed, and
246 no significant interaction for DM, CKD, or CVD was found. There was a significant
247 interaction between retinopathy and HBP in the model ($P=0.045$). Kaplan-Meier curves for
248 all-cause mortality according to retinopathy and systemic vascular conditions are shown in
249 Figure 1. Table 3 presents the synergistic impact of each vascular disorder together with
250 retinopathy on mortality. All-cause mortality for participants with retinopathy and
251 comorbidities such as DM (HR, 1.63; 95% CI, 1.06-2.50; $P=0.027$), HBP (HR, 1.46; 95%
252 CI, 1.03-2.08; $P=0.036$), CKD (HR, 1.71; 95% CI, 1.24-2.35; $P=0.002$) and CVD (HR, 1.88;

253 95% CI, 1.19-2.96; P=0.008) was significantly higher than for those without any condition.
254 The additional effects from vascular comorbidities on all-cause mortality are shown in
255 Supplement Table 3. Overall, co-presence of retinopathy and vascular comorbidities further
256 increased the risk of all-cause mortality than the presence of either health condition, but the
257 increases in risks did not reach statistical significance.

258 The results stratified by diabetes and hypertension status are shown in Supplement Table
259 4. Among non-diabetic participants, all-cause mortality was higher in those with retinopathy
260 and CKD (HR, 1.55; 95% CI, 1.07-2.25; P=0.023). Among diabetic participants, the co-
261 occurrence of retinopathy and CVD (HR, 2.41; 95% CI, 1.15-5.08; P=0.022) further
262 increased all-cause mortality. For participants without hypertension, the co-occurrence of
263 retinopathy and CVD posed a higher risk of death (HR, 3.41; 95% CI, 1.35-8.61; P=0.011).
264 In an analysis limited to participants with hypertension, the joint effect of retinopathy and
265 CKD (HR, 1.83; 95% CI, 1.31-2.54; P=0.001) predicted higher all-cause mortality than that
266 of those without either condition. The sensitivity analysis used inverse probability weighting
267 for addressing the potential non-response bias, which led to similar results as to those
268 reported in the main analysis (Supplement Table 5-7).

269

270 **Discussion**

271 In this large sample of middle-aged and older adults, participants with retinopathy had a
272 higher all-cause mortality rate. Moreover, the co-occurrence of retinopathy and systemic
273 vascular conditions (DM, HBP, CKD, and history of CVD) further increased all-cause

274 mortality.

275 Our findings are in line with previous results that reported a significant association
276 between retinopathy and mortality.¹⁷⁻²⁶ Contrary to the EURODIAB Prospective
277 Complications Study, which found that the relationship between retinopathy and mortality
278 can be largely explained by the presence of coexisting cardiovascular risk factors,³⁹ we report
279 that retinopathy was an independent risk factor for mortality after comprehensive adjustment
280 of covariates. We postulate that the observed difference might be a result of missing fundus
281 photographs (31%) and morbidity data (14%) in the EURODIAB Prospective Complications
282 Study, which may have led to the underestimation of the association between retinopathy
283 and mortality.

284 Only a limited number of studies have attempted to explore the joint effects of
285 retinopathy and systemic vascular comorbidities (such as DM,¹⁶ CKD,^{16, 29-31} and clinical
286 cerebrovascular disease¹⁶) on mortality. A more detailed investigation of systemic vascular
287 comorbidities (DM, HBP, CKD, and CVD) in our study provides further insights into the
288 association between retinopathy and mortality. That is, our results not only support previous
289 findings of a higher mortality risk in individuals with retinopathy but also suggest that
290 retinopathy in the presence of concomitant DM, HBP, CKD or CVD increases the risk of
291 mortality even further.

292 Mechanisms underlying the association between retinopathy and mortality remain
293 unknown. It has been proposed that retinopathy may be an indicator of the burden of CVD
294 risk factors, including dyslipidemia, obesity, hypertension, and smoking.¹⁷ However, our

295 results do not support this theory. Although we found that the distribution of CVD risk factors
296 differed between the no retinopathy and retinopathy groups, retinopathy was found to be an
297 independent risk factor for mortality in the fully adjusted model. Another potential
298 explanation is that retinopathy, as a marker of abnormal microcirculation in the retina, may
299 be an important indicator of systemic micro- and macro-vascular abnormalities.²⁴ These
300 micro- and macrovascular disorders may share similar pathophysiological processes with
301 retinopathy, including endothelial dysfunction, inflammation, apoptosis, and
302 neovascularization.^{40, 41} In addition, the co-occurrence of retinopathy and systemic vascular
303 disorders may reflect a greater burden and/or severity of vascular pathologies, which may
304 explain the further increase in mortality among the participants who have both retinopathy
305 and systemic vascular disorders.

306 Given that retinopathy can be readily detected via non-invasive means, our findings may
307 have several practical implications. Firstly, our finding of a statistically significant
308 association between retinopathy and systemic vascular abnormalities indicates that
309 individuals with retinopathy may benefit from a comprehensive vascular assessment and
310 should be closely monitored. Secondly, the evidence of a further increase risk of mortality
311 among patients with retinopathy and micro- or macrovascular disorders suggests that
312 intensive vascular risk reduction is needed in the management of these patients. Last but not
313 least, our results are of clinical and public health significance in the context of ageing
314 population, highlighting the importance of retinopathy screening. Additionally, our evidence
315 suggests that retinal imaging could be useful for identifying individuals at high risk of

316 mortality, particularly among individuals with systemic vascular comorbidities, which could
317 expand benefits of retinopathy screening beyond the prevention of sight-threatening disease.
318 Of note, current guidelines and procedures vary across countries on who, when and how to
319 conduct retinopathy screening.^{42, 43} The nationwide screening programs are limited.⁴⁴⁻⁴⁶
320 Nevertheless, the expanding role of retinopathy screening noted in the present analysis,
321 together with the emerging of new technologies, such as tele-ophthalmology, portable fundus
322 camera, and artificial intelligence (AI)-based automatic retinal image grading, are improving
323 the cost-effectiveness of the nationwide screening programs.

324 The strengths of this analysis include the use of a large-scale sample with national
325 representativeness, the use of a standardized objective grading protocol to assess retinopathy,
326 access to death records, long-term follow-up and inclusion of a comprehensive range of
327 covariates. However, several potential limitations should also be considered. Firstly,
328 retinopathy status and potential confounders adjusted for in our analysis were assessed on a
329 single occasion. During the follow-up period, the behaviors and/or retinopathy status of the
330 patients may have changed, which may have a direct impact on the outcome. Secondly,
331 discrepancies may exist between the self-reported data and clinically measured data. This
332 may cause underreporting of milder cases and subsequently lead to a bias in the analysis.
333 Thirdly, participants with missing data tended to have systematically higher mortality risk
334 and possibly more severe retinopathy, which might bias our findings. Nevertheless, we built
335 models for the probability of inclusion and using inverse probability weighting for
336 addressing the potential non-response bias in the sensitivity analysis. Findings observed in

337 the sensitivity analysis were consistent with those from the main analysis, thus verifying the
338 robustness of our results. Fourthly, the number of deaths due to cardiovascular disease was
339 relatively small in some subgroup (e.g., 10 in group with retinopathy but no CKD), prevented
340 us from obtaining the robust estimation of joint effects of retinopathy and systemic vascular
341 comorbidities on cardiovascular disease mortality. Further studies are needed to investigate
342 joint effects of retinopathy and comorbidities on specific-cause mortality. Last but not least,
343 we could not exclude the possibility of unmeasured or residual confounding by systemic
344 comorbidities.

345 In summary, our findings suggest that middle-aged and elderly people with retinopathy
346 have increased all-cause mortality. Furthermore, the joint effects of retinopathy and major
347 systemic vascular comorbidities increase the all-cause mortality further. Our results indicate
348 that more extensive risk factor assessment and management of individuals with retinopathy
349 may be beneficial to reduce their mortality rate, especially in patients who have both
350 retinopathy and systemic vascular disorders.

351

352 **Financial Support:** The present work was supported by the Fundamental Research Funds
353 of the State Key Laboratory of Ophthalmology, Project of Investigation on Health Status of
354 Employees in Financial Industry in Guangzhou, China (Z012014075), Science and
355 Technology Program of Guangzhou, China (202002020049). Prof. Mingguang He receives
356 support from the University of Melbourne at Research Accelerator Program and the CERA
357 Foundation. The Centre for Eye Research Australia receives Operational Infrastructure

358 Support from the Victorian State Government. The sponsor or funding organization had no
359 role in the design or conduct of this research.

360

361 **Financial Disclosures:** The author(s) have no proprietary or commercial interest in any
362 materials discussed in this article.

363

364 **Author Contributions:**

365 Study concept and design: Zhu ZT, He MG, Yang XH.

366 Acquisition, analysis, or interpretation: All authors.

367 Drafting of the manuscript: Zhu ZT, Shang XW.

368 Critical revision of the manuscript for important intellectual content: Wang W, Jason H, Chen
369 YF, He MG, Yang XH.

370 Statistical analysis: Zhu ZT, Shang XW, Wang W.

371 Obtained funding: He MG.

372 Administrative, technical, or material support: Zhu ZT, Shang XW, Wang W, He MG, Yang
373 XH.

374 Study supervision: He MG, Yang XH.

375

376 **Abbreviations and Acronyms:**

377 **CVD** = cardiovascular disease; **NHANES** = National Health and Nutrition Examination
378 Survey; **DM** = diabetes mellitus; **HBP** = high blood pressure; **CKD** = chronic kidney disease;
379 **HR** = hazard ratios; **CI** = confidence interval; **ETDRS** = Early Treatment Diabetic
380 Retinopathy Study; **NDI** = National Death Index; **NPR** = non-proliferative retinopathy; **PR**
381 = proliferative retinopathy; **eGFR** = estimated glomerular filtration rate; **ICD** = International
382 Classification of Diseases, Injuries and Causes of death; **BMI** = body mass index; **CRP** = C-
383 reactive protein; **PIR** = poverty income ratio; **SE** = standard errors; **VIF** = variance inflation
384 factors; **IQR** = interquartile range.

385

386 **REFERENCES:**

- 387 1. Olafsdottir E, Andersson DK, Dedorsson I, Stefansson E. The prevalence of retinopathy in subjects with
388 and without type 2 diabetes mellitus. *Acta Ophthalmol* 2014;92(2):133-7.
- 389 2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy.
390 *Diabetes Care* 2012;35(3):556-64.
- 391 3. Wong TY, Klein R, Sharrett AR, et al. The prevalence and risk factors of retinal microvascular
392 abnormalities in older persons: The Cardiovascular Health Study. *Ophthalmology* 2003;110(4):658-66.
- 393 4. Wong TY, Barr EL, Tapp RJ, et al. Retinopathy in persons with impaired glucose metabolism: the
394 Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Am J Ophthalmol* 2005;140(6):1157-9.
- 395 5. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008.
396 *JAMA* 2010;304(6):649-56.

- 397 6. Gunnlaugsdottir E, Halldorsdottir S, Klein R, et al. Retinopathy in old persons with and without diabetes
398 mellitus: the Age, Gene/Environment Susceptibility--Reykjavik Study (AGES-R). *Diabetologia*
399 2012;55(3):671-80.
- 400 7. Zhu Z, Wang W, Scheetz J, et al. Prevalence and risk profile of retinopathy in non-diabetic subjects:
401 National Health and Nutrition Examination Survey 2005 to 2008. *Clin Exp Ophthalmol* 2019;47(9):1173-81.
- 402 8. Cheung CY, Ikram MK, Sabanayagam C, Wong TY. Retinal microvasculature as a model to study the
403 manifestations of hypertension. *Hypertension* 2012;60(5):1094-103.
- 404 9. Khandekar R, Al Hassan A, Al Dhibi H, et al. Magnitude and determinants of diabetic retinopathy among
405 persons with diabetes registered at employee health department of a tertiary Eye Hospital of central Saudi
406 Arabia. *Oman J Ophthalmol* 2015;8(3):162-5.
- 407 10. Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the
408 atherosclerosis risk in communities study. *J Am Soc Nephrol* 2004;15(9):2469-76.
- 409 11. Wong TY, Klein R, Amirul Islam FM, et al. Three-year incidence and cumulative prevalence of
410 retinopathy: the atherosclerosis risk in communities study. *Am J Ophthalmol* 2007;143(6):970-6.
- 411 12. Qiu C, Cotch MF, Sigurdsson S, et al. Retinal and cerebral microvascular signs and diabetes: the age,
412 gene/environment susceptibility-Reykjavik study. *Diabetes* 2008;57(6):1645-50.
- 413 13. Wong TY, Rosamond W, Chang PP, et al. Retinopathy and risk of congestive heart failure. *JAMA*
414 2005;293(1):63-9.
- 415 14. Grunwald JE, Ying GS, Maguire M, et al. Association between retinopathy and cardiovascular disease in
416 patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). *Am J*
417 *Cardiol* 2012;110(2):246-53.
- 418 15. Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic

- 419 retinopathy: the Japan Diabetes Complications Study. *Ophthalmology* 2013;120(3):574-82.
- 420 16. Fisher DE, Jonasson F, Klein R, et al. Mortality in Older Persons with Retinopathy and Concomitant
421 Health Conditions: The Age, Gene/Environment Susceptibility-Reykjavik Study. *Ophthalmology*
422 2016;123(7):1570-80.
- 423 17. Van Hecke MV, Dekker JM, Nijpels G, et al. Retinopathy is associated with cardiovascular and all-cause
424 mortality in both diabetic and nondiabetic subjects: the hoorn study. *Diabetes Care* 2003;26(10):2958.
- 425 18. Xu L, Wang YX, Xie XW, Jonas JB. Retinopathy and mortality. The Beijing Eye Study. *Graefes Arch Clin*
426 *Exp Ophthalmol* 2008;246(6):923-5.
- 427 19. Sairenchi T, Iso H, Yamagishi K, et al. Mild retinopathy is a risk factor for cardiovascular mortality in
428 Japanese with and without hypertension: the Ibaraki Prefectural Health Study. *Circulation* 2011;124(23):2502-
429 11.
- 430 20. Juutilainen A, Lehto S, Ronnema T, et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic
431 men and women. *Diabetes Care* 2007;30(2):292-9.
- 432 21. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO
433 Multinational Study of Vascular Disease in Diabetes. *Diabetologia* 2001;44 Suppl 2:S54-64.
- 434 22. Cusick M, Meleth AD, Agron E, et al. Associations of mortality and diabetes complications in patients
435 with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. *Diabetes Care*
436 2005;28(3):617-25.
- 437 23. Wong TY, Klein R, Nieto FJ, et al. Retinal microvascular abnormalities and 10-year cardiovascular
438 mortality: a population-based case-control study. *Ophthalmology* 2003;110(5):933-40.
- 439 24. Liew G, Wong TY, Mitchell P, et al. Retinopathy predicts coronary heart disease mortality. *Heart*
440 2009;95(5):391-4.

- 441 25. Mitchell P, Wang JJ, Wong TY, et al. Retinal microvascular signs and risk of stroke and stroke mortality.
442 *Neurology* 2005;65(7):1005-9.
- 443 26. Longstreth W, Jr., Larsen EK, Klein R, et al. Associations between findings on cranial magnetic resonance
444 imaging and retinal photography in the elderly: the Cardiovascular Health Study. *Am J Epidemiol*
445 2007;165(1):78-84.
- 446 27. Frith E, Loprinzi PD. Retinopathy and Mortality. *Diabetes Spectr* 2018;31(2):184-8.
- 447 28. Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and
448 cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. *Diabetes Care*
449 2011;34(5):1238-44.
- 450 29. Ricardo AC, Grunwald JE, Parvathaneni S, et al. Retinopathy and CKD as predictors of all-cause and
451 cardiovascular mortality: National Health and Nutrition Examination Survey (NHANES) 1988-1994. *Am J*
452 *Kidney Dis* 2014;64(2):198-203.
- 453 30. Li YH, Sheu WH, Lee IT. Effects of retinopathy and chronic kidney disease on long-term mortality in type
454 2 diabetic inpatients with normal urinary albumin or protein: a retrospective cohort study. *BMJ Open*
455 2018;8(7):e021655.
- 456 31. Pavkov ME, Harding JL, Chou CF, Saaddine JB. Prevalence of Diabetic Retinopathy and Associated
457 Mortality Among Diabetic Adults With and Without Chronic Kidney Disease. *Am J Ophthalmol* 2019;198:200-
458 8.
- 459 32. Armstrong RA. Alzheimer's Disease and the Eye. *Journal of Optometry* 2009;2(3):103-11.
- 460 33. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified
461 Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research
462 Group. *Ophthalmology* 1991;98(5 Suppl):786-806.

- 463 34. Klein R, Klein BE, Magli YL, et al. An alternative method of grading diabetic retinopathy. *Ophthalmology*
464 1986;93(9):1183-7.
- 465 35. Klein R, Meuer SM, Moss SE, et al. Detection of age-related macular degeneration using a nonmydriatic
466 digital camera and a standard film fundus camera. *Arch Ophthalmol* 2004;122(11):1642-6.
- 467 36. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the
468 United States. *JAMA Ophthalmol* 2014;132(11):1334-40.
- 469 37. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern*
470 *Med* 2009;150(9):604-12.
- 471 38. Loprinzi PD, Addoh O. Predictive Validity of the American College of Cardiology/American Heart
472 Association Pooled Cohort Equations in Predicting All-Cause and Cardiovascular Disease-Specific Mortality
473 in a National Prospective Cohort Study of Adults in the United States. *Mayo Clin Proc* 2016;91(6):763-9.
- 474 39. van Hecke MV, Dekker JM, Stehouwer CD, et al. Diabetic retinopathy is associated with mortality and
475 cardiovascular disease incidence: the EURODIAB prospective complications study. *Diabetes Care*
476 2005;28(6):1383-9.
- 477 40. Barger AC, Beuwkes R, 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and
478 neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. *N*
479 *Engl J Med* 1984;310(3):175-7.
- 480 41. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation,
481 and apoptosis in diabetes mellitus. *Mediators Inflamm* 2010;2010:792393.
- 482 42. Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of
483 Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource
484 Settings. *Ophthalmology* 2018;125(10):1608-22.

485 43. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American

486 Diabetes Association. *Diabetes Care* 2017;40(3):412-8.

487 44. Kristinsson JK, Hauksdottir H, Stefansson E, et al. Active prevention in diabetic eye disease. A 4-year

488 follow-up. *Acta Ophthalmol Scand* 1997;75(3):249-54.

489 45. Gillow JT, Gray JA. The National Screening Committee review of diabetic retinopathy screening. *Eye*

490 (Lond) 2001;15(Pt 1):1-2.

491 46. Diabetic Retina Screen. Diabetic RetinaScreen—The National Diabetic Retinal Screening Programme.

492 <http://www.diabeticretinascreen.ie/> (accessed Aug 19, 2020).

493

494

495 Table 1. Demographic, Health-Related Behaviors and General Health Characteristics of Participants With
496 and Without Retinopathy.

Characteristics	Overall, N=5703	No Retinopathy, n = 4993 (%)	Any Retinopathy, n = 710 (%)	Unadjusted P Value ^a
Age (SE), yrs	56.5 (0.38)	56.1 (0.37)	60.1 (0.77)	<0.001
Gender				
Male	2855 (47.4)	2466 (46.6)	389 (55.0)	<0.001
Female	2848 (52.6)	2527 (53.4)	321 (45.0)	
Race				
Non-Hispanic white	3059 (77.1)	2761 (78.1)	298 (67.8)	<0.001
Non-Hispanic black	1174 (9.66)	963 (9.00)	211 (15.8)	
Mexican American	884 (5.43)	757 (5.24)	127 (7.19)	
Other	586 (7.83)	512 (7.68)	74 (9.24)	
Education				
Less than high school	1682 (18.1)	1405 (17.3)	277 (25.8)	<0.001
High school and over	4021 (81.9)	3588 (82.7)	433 (74.2)	
Marital status ^b				
Unmarried and other	2071 (31.1)	1804 (30.9)	267 (32.4)	0.430
Married/with a partner	3629 (68.9)	3186 (69.1)	443 (67.6)	
Poverty income ratio (PIR) ^b				
Below poverty (<1)	841 (9.29)	729 (9.21)	112 (10.0)	0.489
At or above poverty (≥1)	4460 (90.7)	3914 (90.8)	546 (90.0)	
Smoking status ^b				
Never	2687 (48.3)	2347 (48.4)	340 (47.6)	0.770
Former/Current	3012 (51.7)	2642 (51.6)	370 (52.4)	
Alcohol consumption ^b				
Lifetime abstainer/former	1380 (20.6)	1158 (19.4)	222 (31.1)	<0.001

<hr/>				
drinker				
Current drinker	4181 (79.4)	3710 (80.6)	471 (68.9)	
Hypercholesterolaemia ^b				
No	2606 (48.4)	2326 (48.9)	280 (43.8)	0.096
Yes	2940 (51.6)	2530 (51.1)	410 (56.2)	
BMI (SE), kg/m ²	29.1 (0.14)	29.0 (0.15)	30.0 (0.27)	0.001
High C-reactive protein ^b				
No	4876 (89.4)	4282 (89.4)	594 (89.1)	0.840
Yes	634 (10.6)	547 (10.6)	87 (10.9)	
Walking disability				
No	5088 (91.7)	4491 (92.4)	597 (86.0)	<0.001
Yes	615 (8.26)	502 (7.64)	113 (14.0)	
Self-rated health ^b				
Poor/Fair	1466 (18.8)	1191 (17.4)	275 (32.2)	<0.001
Good/Excellent	4111 (81.2)	3692 (82.6)	419 (67.8)	
DM ^b				
No	4432 (85.7)	4091 (88.6)	341 (58.2)	<0.001
Yes	1129 (14.4)	772 (11.4)	357 (41.8)	
Diabetes duration (SE), yrs	1.39 (0.09)	0.88 (0.06)	6.18 (0.43)	<0.001
HBP ^b				
No	2784 (56.2)	2565 (57.8)	219 (41.2)	<0.001
Yes	2824 (43.8)	2356 (42.2)	468 (58.8)	
CKD ^b				
No	4088 (80.5)	3704 (82.2)	384 (65.0)	<0.001
Yes	1413 (19.5)	1113 (17.8)	300 (35.0)	
CVD				
No	4796 (87.8)	4285 (89.0)	511 (76.2)	<0.001
<hr/>				

Yes	907 (12.2)	708 (11.0)	199 (23.8)
-----	------------	------------	------------

Abbreviations: SE, standard error; BMI, body mass index; DM, diabetes mellitus; HBP, high blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease. Boldface indicates statistical significance.

All proportions are weighted estimates of the US population characteristics, taking into account the complex sampling design of the National Health and Nutrition Examination Survey.

^a All P values were calculated using t-test for continuous variables and the design-adjusted Rao-Scott Pearson χ^2 test for categorical variables.

^b Participants with missing data (marital status: 3, income level: 402, smoking status: 4, alcohol consumption: 142, hypercholesterolaemia: 157, level of C-reactive protein: 193, self-rated health: 126, DM: 142, HBP: 95, CKD: 202).

498 Table 2. All-Cause Mortality by Demographic, Health-Related Behaviors and General Health
499 Characteristics

Characteristics	No. of	No. of	HR (95% CI) ^a
	Living Subjects, n = 4754 (%)	Deceased Subjects, n = 949 (%)	
Age (SE), yrs	54.9 (0.35)	68.7 (0.57)	1.10 (1.09-1.11)
Gender			
Male	2294 (46.7)	561 (52.7)	Reference
Female	2460 (53.3)	388 (47.3)	0.68 (0.58-0.81)
Race			
Non-Hispanic white	2470 (76.8)	589 (78.8)	Reference
Non-Hispanic black	977 (9.52)	197 (10.7)	1.55 (1.31-1.83)
Mexican American	779 (5.55)	105 (4.54)	1.30 (1.02-1.67)
Other	528 (8.09)	58 (5.92)	1.12 (0.71-1.76)
Education			
Less than high school	1290 (16.1)	392 (33.6)	Reference
High school and over	3464 (83.9)	557 (66.4)	0.57 (0.48-0.68)
Marital status ^b			
Unmarried and other	1627 (29.2)	444 (45.3)	Reference
Married/with a partner	3124 (70.8)	505 (54.7)	0.62 (0.54-0.72)
Poverty income ratio (PIR) ^b			
Below poverty (<1)	650 (8.39)	191 (16.3)	Reference
At or above poverty (≥1)	3781 (91.6)	679 (83.7)	0.44 (0.34-0.56)
Smoking status ^b			
Never	2334 (50.1)	353 (35.1)	Reference
Former/Current	2417 (49.9)	595 (64.9)	1.64 (1.38-1.95)
Alcohol consumption ^b			

Lifetime abstainer/former drinker	1094 (19.3)	286 (30.6)	Reference
Current drinker	3549 (80.7)	632 (69.4)	0.73 (0.63-0.84)
Hypercholesterolaemia ^b			
No	2195 (48.7)	411 (45.7)	Reference
Yes	2445 (51.3)	495 (54.3)	0.88 (0.75-1.02)
BMI (SE), kg/m ²	29.2 (0.15)	28.2 (0.22)	0.99 (0.97-1.01)
High C-reactive protein ^b			
No	4137 (90.2)	739 (82.9)	Reference
Yes	481 (9.76)	153 (17.1)	2.05 (1.49-2.81)
Walking disability			
No	4386 (94.1)	702 (74.1)	Reference
Yes	368 (5.91)	247 (25.9)	2.77 (2.26-3.40)
Self-rated health ^b			
Poor/Fair	1086 (16.2)	380 (38.4)	Reference
Good/Excellent	3570 (83.8)	541 (61.6)	0.38 (0.33-0.44)
DM ^b			
No	3796 (87.3)	636 (73.0)	Reference
Yes	848 (12.7)	281 (27.0)	1.75 (1.40-2.19)
Diabetes duration (SE), yrs	1.14 (0.07)	3.28 (0.36)	1.02 (1.02-1.03)
HBP ^b			
No	2490 (59.1)	294 (34.0)	Reference
Yes	2201 (40.9)	623 (66.0)	1.31 (1.07-1.61)
CKD ^b			
No	3658 (84.5)	430 (50.5)	Reference
Yes	938 (15.5)	475 (49.5)	1.93 (1.64-2.26)
CVD			
No	4195 (90.9)	601 (63.9)	Reference

Yes	559 (9.07)	348 (36.1)	2.17 (1.88-2.49)
-----	------------	------------	-------------------------

Abbreviations: SE, standard error; BMI, body mass index; DM, diabetes mellitus; HBP, high blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease. Boldface indicates statistical significance.

All-cause mortality was assessed through December 31, 2015. All proportions, means and standard errors are weighted estimates of the US population characteristics, taking into account the complex sampling design of the National Health and Nutrition Examination Survey.

^a Adjusted for age and gender.

^b Participants with missing data (marital status: 3, income level: 402, smoking status: 4, alcohol consumption: 142, hypercholesterolaemia: 157, level of C-reactive protein: 193, self-rated health: 126, DM: 142, HBP: 95, CKD: 202).

501 Table 3. Cox Proportional Hazards Regression Models of All-Cause Mortality by Retinopathy Status and
502 Concomitant Medical Conditions.

	No. of Events	Mortality Rate ^a	Model 1 ^b	Model 2 ^c	P for Interaction ^d
Retinopathy and DM status					0.529
Neither retinopathy nor DM (N = 4091)	563	9.36%	1.00 (reference)	1.00 (reference)	
Retinopathy only (N = 341)	73	17.9%	1.70 (1.33-2.16)	1.49 (1.16-1.90)	
DM only (N = 772)	167	18.6%	1.52 (1.15-2.00)	1.27 (0.99-1.64)	
Both DM and retinopathy (N = 357)	114	30.3%	2.17 (1.54-3.06)	1.63 (1.06-2.50)	
Retinopathy and HBP status					0.045
Neither retinopathy nor HBP (N = 2565)	253	6.56%	1.00 (reference)	1.00 (reference)	
Retinopathy only (N = 219)	41	12.5%	2.04 (1.35-3.10)	2.06 (1.32-3.24)	
HBP only (N = 2356)	485	15.6%	1.28 (1.03-1.60)	1.19 (0.93-1.52)	
Both HBP and retinopathy (N = 468)	138	29.1%	1.98 (1.44-2.70)	1.46 (1.03-2.08)	
Retinopathy and CKD status					0.054
Neither retinopathy nor CKD (N = 3704)	370	6.71%	1.00 (reference)	1.00 (reference)	
Retinopathy only (N = 384)	60	13.9%	1.83 (1.27-2.64)	1.70 (1.20-2.41)	
CKD only (N = 1113)	353	27.3%	1.82 (1.55-2.14)	1.43 (1.14-1.78)	
Both CKD and retinopathy (N = 300)	122	39.5%	2.74 (2.04-3.69)	1.71 (1.24-2.35)	
Retinopathy and CVD status					0.062
Neither retinopathy nor CVD (N = 4285)	502	7.80%	1.00 (reference)	1.00 (reference)	
Retinopathy only (N = 511)	99	16.7%	1.82 (1.39-2.38)	1.69 (1.29-2.21)	
CVD only (N = 708)	257	32.7%	2.07 (1.79-2.39)	1.75 (1.45-2.11)	
Both CVD and retinopathy (N = 199)	91	43.1%	2.85 (2.02-4.03)	1.88 (1.19-2.96)	

Abbreviations: DM, diabetes mellitus; HBP, high blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease.

Boldface indicates statistical significance. Values are hazard ratios (95% confidence interval).

All-cause mortality was assessed through December 31, 2015.

^a All proportions are weighted estimates of the US population characteristics, taking into account the complex sampling design of the National Health and Nutrition Examination Survey.


^b Model 1: Adjusted for age, gender, race, education level, marital status, income status.

^c Model 2: Model 1 plus additional adjustments for BMI, smoking status, drinking status, hypertension, diabetes mellitus, diabetes duration, hypercholesterolaemia, C-reactive protein, self-rated health status, walking disability, self-reported history of cardiovascular disease and chronic kidney disease.

^d Interaction between retinopathy and either DM, HBP, CKD, or CVD.

503

504



505

506 **Figure 1.** Kaplan-Meier curve showing all-cause mortality rate by retinopathy status and
507 concomitant systemic vascular disorders (A: diabetes mellitus; B: high blood pressure; C:
508 chronic kidney disease; D: history of cardiovascular disease), using the 2005-2008 National
509 Health and Nutrition Examination Survey (NHANES). All-cause mortality was assessed
510 through December 31, 2015. Risk of mortality was further increased among those with both
511 retinopathy and systemic vascular diseases compared to participants without either condition.

512

513 Supplement Digital Content 1.

514 **Supplement Table 1.** Demographic, Health-Related Behaviors and General Health

515 Characteristics of Participants Included and Excluded in the Analysis.

516 Supplement Digital Content 2.

517 **Supplement Table 2.** Stratified Analysis of Cox Proportional Hazards Regression Models

518 of All-Cause Mortality by Retinopathy Status and Systemic Vascular Diseases.

519 Supplement Digital Content 3.

520 **Supplement Table 3.** Additional Effects from Vascular Comorbidities on All-Cause
521 Mortality Using Cox Proportional Hazards Regression Models.

522 Supplement Digital Content 4.

523 **Supplement Table 4.** Stratified Analysis of Cox Proportional Hazards Regression Models
524 of All-Cause Mortality by Retinopathy Status and Concomitant Medical Conditions.

525 Supplement Digital Content 5.

526 **Supplement Table 5.** Cox Proportional Hazards Regression Models of All-Cause Mortality
527 by Retinopathy Status and Retinopathy Severity using Inverse Probability Weighting.

528 Supplement Digital Content 6.

529 **Supplement Table 6.** Cox Proportional Hazards Regression Models of All-Cause Mortality
530 by Retinopathy Status and Concomitant Medical Conditions using Inverse Probability
531 Weighting.

532 Supplement Digital Content 7.

533 **Supplement Table 7.** Stratified Analysis of Cox Proportional Hazards Regression Models
534 of All-Cause by Retinopathy Status and Concomitant Medical Conditions using Inverse
535 Probability Weighting.

536